Myomo Inc (MYO) — Titan Protect Analysis

MYO

Myomo Inc

Healthcare · ·

$1.28

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$40M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-4.05

Based on estimated future earnings — lower means cheaper

Rev Growth

+2.9%

Year-over-year revenue change

Profit Margin

-36.7%

How much profit the company keeps from each dollar of revenue

ROE

-98.5%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$3.00

+134% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 5 analysts covering this stock

About Myomo Inc

Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides MyoPro 2 that includes control technology, configuration software and user interfac

https://myomo.com

Country: United States Employees: 194 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

-0.094

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0334

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.434

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-39.4%

Historical annualised return based on price data

Max Drawdown

-90.8%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.39

Moves slightly more than the broader market

52W High

$3.08

58% below the year high

52W Low

$0.61

112% above the year low

Avg Volume

417,850

Average daily shares traded — higher means easier to buy and sell

Short Ratio

10.8

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.36

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

210.65

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

66.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-31.2%

Profit from core operations before interest and tax

Free Cash Flow

$-10,472,450

Negative — the business is spending more than it generates

Revenue (TTM)

$41M

Total revenue over the last 12 months

Net Income

$-15,118,225

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$9.50

Target Median

$3.00

Target Low

$1.10

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go